JP Morgan Chase’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-15,085
| Closed | -$73K | – | 5916 |
|
|
2020
Q1 | $73K | Buy |
15,085
+97
| +0.6% | +$629 | ﹤0.01% | 4617 |
|
|
2019
Q4 | $159K | Buy |
14,988
+294
| +2% | +$2.92K | ﹤0.01% | 4756 |
|
|
2019
Q3 | $153K | Buy |
14,694
+3,690
| +34% | +$48.3K | ﹤0.01% | 4741 |
|
|
2019
Q2 | $166K | Buy |
11,004
+1,715
| +18% | +$24.8K | ﹤0.01% | 4737 |
|
|
2019
Q1 | $119K | Buy |
9,289
+2,067
| +29% | +$23.4K | ﹤0.01% | 4827 |
|
|
2018
Q4 | $69K | Buy |
7,222
+673
| +10% | +$8.73K | ﹤0.01% | 4980 |
|
|
2018
Q3 | $109K | Buy |
6,549
+937
| +17% | +$15K | ﹤0.01% | 4917 |
|
|
2018
Q2 | $90K | Buy |
5,612
+264
| +5% | +$4.71K | ﹤0.01% | 4879 |
|
|
2018
Q1 | $82K | Sell |
5,348
-46,995
| -90% | -$733K | ﹤0.01% | 4660 |
|
|
2017
Q4 | $817K | Buy |
52,343
+51,550
| +6,501% | +$689K | ﹤0.01% | 3838 |
|
|
2017
Q3 | $9K | Buy |
+793
| New | +$7.46K | ﹤0.01% | 4742 |
|
|
2017
Q1 | – | Sell |
-25,121
| Closed | -$269K | – | 5328 |
|
|
2016
Q4 | $269K | Buy |
25,121
+22,632
| +909% | +$274K | ﹤0.01% | 4043 |
|
|
2016
Q3 | $27K | Sell |
2,489
-1,211
| -33% | -$9.85K | ﹤0.01% | 4145 |
|
|
2016
Q2 | $25K | Buy |
+3,700
| New | +$23.4K | ﹤0.01% | 4186 |
|
|
2013
Q4 | – | Sell |
-142,837
| Closed | -$6.47M | – | 4319 |
|
|
2013
Q3 | $6.47M | Sell |
142,837
-61,308
| -30% | -$2M | ﹤0.01% | 2032 |
|
|
2013
Q2 | $4.87M | Buy |
+204,145
| New | +$3.25M | ﹤0.01% | 2149 |
|
JP Morgan Chase's STML Position: Q2 2020 in Review
JP Morgan Chase sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 15,085 shares — an estimated $73K sold.
JP Morgan Chase first reported a position in STML in Q2 2013 and held it in 16 quarters. The position peaked at $6.47M in Q3 2013. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- JP Morgan Chase reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- JP Morgan Chase sold 15,085 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $73K.
- JP Morgan Chase first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 16 quarters.
- JP Morgan Chase's Stemline Therapeutics, Inc. position peaked at $6.47M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on JP Morgan Chase's 13F filing for Q2 2020, filed 11 Aug 2020.